| Breast Cancer |
1 |
0.99 |
| HER2-Positive Breast Cancer |
0 |
0.75 |
| Triple Negative Breast Cancer |
0 |
0.75 |
| Cancer |
0 |
0.65 |
| Breast |
0 |
0.61 |
| Antineoplastic Drug |
0 |
0.55 |
| Bladder Cancer |
0 |
0.47 |
| Chemotherapy |
0 |
0.39 |
| Healthcare and Medical Technology |
0 |
0.1 |
| Hodgkin Lymphoma |
0 |
0.1 |
| Antibody Drug Conjugates |
0 |
0.09 |
| Biomedical Technology |
0 |
0.09 |
| Endocrine Therapy |
0 |
0.09 |
| Humanized Monoclonal Antibody |
0 |
0.09 |
| Receptors |
0 |
0.09 |
| White Blood Cell Count |
0 |
0.06 |
| Diarrhea |
0 |
0.05 |
| Accomodation |
0 |
0.04 |
| Antigens |
0 |
0.04 |
| Bladder |
0 |
0.04 |
| Blood |
0 |
0.04 |
| California |
0 |
0.04 |
| Estrogen |
0 |
0.04 |
| Food and Drug Administration (FDA) |
0 |
0.04 |
| Travel Medicine |
0 |
0.04 |